Join the inaugural Rare Conversations Conference aimed at facilitating essential discussion on the future of the rare disease and OMP ecosystem involving leading experts.
The event will bring together thought leaders across regulators, payers, patient organizations, research, academia, EU institutions, industry and investors to develop inspiring ideas to advance the future of rare diseases. In four sessions, speakers will cover the entire rare disease and orphan drug value chain from research through to access.
Be part of this multifaceted and holistic approach to improving the rare disease ecosystem for the next decade and beyond in the EU through true multi-stakeholder exchange.
The event is organized by Alexion in cooperation with the European rare disease patient organisation EURORDIS, the European Joint Programme on Rare Diseases EJP RD, the body for small to medium-sized innovative pharmaceutical, biotechnology and medical technology companies EUCOPE, and the association of the biotech industry EuropaBio.
Block your calendar for 9th November from 14.00 – 18.00 CET. More information and the registration link will be shared with you shortly.
About “Rare Conversations”
Rare Conversations is an event series organized by Alexion to educate on rare diseases and facilitate multi-stakeholder exchange, tackling timely topics of interest such as the revision of the OMP Regulation. Rare Conversations aims to unite and engage the rare disease community, including key stakeholders in Brussels and EU Member States. Since its inception in December 2020, four Rare Conversations have taken place, each in cooperation with a different partner and focused on specific topics, such as COVID and rare diseases, the specificities of research in rare disease, and EU and national value assessment for orphan drugs. People with rare diseases always stay at the centre of our activities and are part of every event.
Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.
Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.
The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.
Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.
Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.
Algal Omage-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of algal omega-3 used.